Heart risk alert: troponin test may protect cancer patients on immunotherapy

NCT ID NCT06007274

Completed Knowledge-focused Sponsor: Institut Mutualiste Montsouris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily stopping cancer treatment. Researchers also checked whether this monitoring affected how much cancer therapy patients could complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could show that routine troponin monitoring helps catch heart issues early in cancer patients on immunotherapy, potentially preventing serious events.
What could go wrong: This is a retrospective study, not a controlled trial, so it can only suggest associations, not prove cause and effect. The results may not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER CARDIOVASCULAR BIOMARKERS IMMUNE CHECKPOINT INHIBITOR

Contacts and locations

Locations

Institut Mutualiste Montsouris

Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.